anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Studies have shown that properly performed an interpreted skin tests with ragweed pollen extract are useful in the diagnosis of allergy to ragweed pollen 7, 8, 20, 21. Immunotherapy with the appropriate dosage of short ragweed pollen extract is effective in reducing symptoms of hay fever and asthma resulting from exposure to short ragweed pollen (9, 10, 11), and it is believed to be effective with extract of giant ragweed, although carefully controlled studies are unavailable. However, clinical observations and known cross reactivity between short and giant ragweed pollens have led to the practice of using a mixture of the two species for skin testing and treatment 22, 23, 24, 25, 26, 27.   
This form of treatment is recommended for patients who cannot avoid exposure to pollen and who do not obtain satisfactory relief of symptoms from other medications, such as antihistamines. Immunologic changes resulting from treatment with short ragweed pollen extract are believed to include:   


  1. The induction of specific anti-ragweed IgG antibodies commonly referred to as "blocking antibodies" 12, 13. 
  2. A decrease in the elevation of ragweed specific IgE during and immediately following the ragweed pollen season 14. 
  3. A reduction of circulating anti-ragweed IgE after long-term immunotherapy 15. 
  4. A decrease in skin reactivity to the extract 16 and a decrease in leukocyte sensitivity to histamine release 17 after long-term immunotherapy.
518,515. Tubercle vaccines. HASHIMOTO, T., and TSURUHARA, F. July 19, 1938, No. 21468. [Class 81 (i)] A tubercular vaccine consisting of non-acidfast bacilli is prepared by the exposure of tubercle bacilli to a halogen gas especially bromine, chlorine and iodine. A suspension of tubercle bacilli is smeared over the inner surface of a glass tube and dried, the interior being then filled with bromine, chlorine or iodine gas and so kept for 10 to 20 minutes. The bacilli are then suspended in sterilized salt solution.
PURPOSE: A hair cosmetic composition containing natural proteins and metal ions is provided to enhance hair volume or elasticity with softness. CONSTITUTION: A hair cosmetic composition contains 0.005-20.0 weight% of natural proteins and 0.005-10.0 weight% of metal ions as an active ingredient. The natural protein is a protein isolated from wheat, soybean, corn, or pearl. The natural protein is hydrolysed conchiolin protein. The metal ion is iron, zinc, copper, aluminum ion. The hair composition is used for hair glossiness and hair strengthening. The cosmetic composition is manufactured in the form of hair serum, hair lotion, hair cream, hair essence, hair oil, scalp treatment, shampoo, rinse, hair conditioner, styling gel, hair mousse, hair wax, or hair spray.
In one aspect, the invention relates to a method of treating muscle atrophy by providing an effective amount of a compound to an animal in need thereof. The compounds can modulate the expression levels of multiple mrnas of a muscle wasting marker. This abstract is intended as a scanning tool for searching in the particular art and is not intended to be limiting of the present invention. The disclosed compounds can treat muscle atrophy when administered in an effective amount to an animal such as a mammal, fish, or bird. Also disclosed are methods of reducing blood glucose in an animal by administering ursolic acid or an ursolic acid analog such as a betulinic acid analog, and an allantoin analog such as naringenin to the animal in an effective amount. Also disclosed are methods of reducing blood glucose in an animal by administering to the animal an allicin/allicin analog, such as allicin, in an effective amount. The disclosed compounds can also promote muscle health, promote normal muscle function, and/or promote healthy aging muscle by providing an effective amount of the disclosed compounds to a subject in need thereof.
Women with significant hypertension should not be started on hormonal contraception98. An increase in blood pressure has been reported in women taking oral contraceptives68 and this increase is more likely in older oral contraceptive users69 and with extended duration of use61. Data from the Royal College of General Practitioners12 and subsequent randomized trials have shown that the incidence of hypertension increases with increasing progestational activity.

Women with a history of hypertension or hypertension-related diseases, or renal disease70 should be encouraged to use another method of contraception. If women elect to use oral contraceptives, they should be monitored closely and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping oral contraceptives, and there is no difference in the occurrence of hypertension between former and never users68–71. It should be noted that in two separate large clinical trials (N=633 and N=911), no statistically significant changes in mean blood pressure were observed with ORTHO-CYCLEN®.
The invention relates to a counter-fact-based cognitive impairment digital drug effect evaluation method. An evaluation system adopted by the method comprises an intervention treatment end, matched equipment and an effect evaluation module. The intervention therapy side can be used for performing treatment/intervention related to cognitive impairment on the user, and at least can acquire input data input by the user through the intervention therapy side. The corollary equipment can gather the time sequence action data corresponding to the input data that the user produces when using the intervention treatment end to carry out treatment/intervention. The effect evaluation module can acquire input data and time sequence action data corresponding to the input data from the intervention treatment end and the matched equipment respectively. The effect evaluation module can analyze the input data and the time sequence action data corresponding to the input data based on the inverse fact theory to generate an evaluation report for evaluating the treatment/intervention of the intervention treatment end on the user, and screen out core characteristics in the treatment/intervention. The method can be used in the system.
The obesity epidemic is one of the foremost threats to the health of children and adults in the U.S today. Multidisciplinary pediatric weight management programs have been deemed effective, with increased access to these programs strongly advocated. However, the effectiveness of these programs is limited by attrition, with dropout ranging from 27-73%, limiting health benefits to children and inefficiently utilizing already scarce resources. In addition to better understanding the drivers of attrition, being able to predict or forecast dropout holds great potential to improve adherence and outcomes, and modify treatment approaches to best serve the needs of families. Using a model that isolates variables associated with attrition from pediatric weight management to forecast participant dropout, this prospective, longitudinal observational study will collect comprehensive data on child and family-, obesity-, and treatment-related variables In Stage 1, investigators will install an attrition forecasting model, the Outcomes Forecasting System (OFS), in 3 pediatric weight management programs, and build its precision and calibration using a conceptual model of adherence. In Stage 2, we will establish external validation, installing the OFS in a fourth weight management program, and temporal validation through continued use of the OFS within the 3 original sites. The overall goal of this project is to increase the accuracy and power of an attrition prediction model through its installation in weight management programs and to demonstrate its internal, external, and temporal validity. A greater understanding of patient, family, and disease-specific factors that predict dropout from pediatric weight management can be utilized to prevent attrition. By identifying the most pertinent factors driving attrition across weight management sites, new avenues for treatment and prevention will be identified. This project will result in a valuable tool, available for dissemination across a diverse array of clinical programs to improve adherence, decrease costs, and improve outcomes.
The invention belongs to the technical field of biology, and relates to a blocking ELISA kit for detecting an N protein antibody of Porcine Epidemic Diarrhea Virus (PEDV). The kit comprises: an ELISA plate coated with PEDV N protein, an HRP-labeled PEDV N protein monoclonal antibody, a positive serum control and a negative serum control. The PEDV N protein monoclonal antibody is 1F10, the amino acid sequence of the heavy chain variable region of the monoclonal antibody 1F10 is shown as SEQ ID NO. 3, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 4. The kit has no cross reaction with the common porcine diarrhea related virus positive serum, and the intra-batch and inter-batch repeated variation coefficient is less than 10%. The coincidence rate of the detection of the blocking ELISA kit and the foreign commercialized kit is 98.79%, the Kappa value is 0.95, and the detection of the blocking ELISA kit and the foreign commercialized kit are highly consistent.
Participants will complete a 5-day intervention blocks where they receive daily AIH followed by task specific airway protection training 60 minutes after the AIH exposure. Each exposure involves a 1-minute delivery of low oxygen (9-11% inspired O2), followed by a 1.5-min interval of room air breathing (21% O2). This method of waiting 45-60 minutes after the delivery of AIH and prior to engaging in task-specific training/rehabilitation enables sufficient time to increase brain derived neurotrophic factor (BDNF) following AIH, thereby augmenting the impact of task-specific training.
PURPOSE: A Streptomyces sp. AN1542 strain having an antibacterial activity and a compound using the same are provided to enhance antibacterial effect against MRSA, QRSA, VRSA and VRE and to treat infectious diseases. CONSTITUTION: A Streptomyces sp. AN1542 strain(deposit number:KCTC 12113BP) has an antibacterial effect. An antibacterial composition contains a compound of chemical formula 1 or 2 or isomer, derivative, or pharmaceutically acceptable salt thereof, a strain producing the compounds, spore thereof, bacteria body, or culture thereof. The composition is a pharmaceutical or quasi-drug composition. A method for preparing the compound or isomer, derivative, or pharmaceutically acceptable salt thereof comprises: a step of culturing the strain or mutant strain; a step of extracting the culture and mycelium of the strain with an organic solvent to obtain ethyl acetate; and a step of performing chromatography to the ethyl acetate extract.
BACKGROUND: Impacted mandibular third molars occasionally are in intimate relation to the inferior alveolar nerve (IAN). Coronectomy has been proposed as a good alternative to prevent injury of the IAN. The present study evaluates the clinical and radiological outcomes of impacted mandibular third molars presenting radiographic signs associated with a high risk of IAN injury, and which were treated with the coronectomy technique.
MATERIAL AND METHODS: A retrospective case series evaluated the outcomes of coronectomies of impacted mandibular third molars. The inclusion criteria were: available preoperative, immediate postoperative and two-year panoramic radiographs, preoperative cone-beam computed tomography (CBCT), and a complete case history. The clinical evaluation comprised intraoperative complications (mobilized fragments of root and damage to adjacent structures), short-term complications (sensory alterations and postoperative infection), and long-term complications (infection or oral exposure). The IAN position with respect to the roots, root shape, eruption status, third molar position, radicular-complex migration and bone above roots were radiographically evaluated as well.
RESULTS: Approximately a total of 2000 mandibular third molars were removed from 2011 to 2022. Of these, 39 molars in 34 patients were partially extracted using the coronectomy technique. The mean age was 36 years (range 22-77), and the mean follow-up was 28 months (range 24-84). There were two short-term postoperative infections. One of them was resolved through reintervention to remove the roots after antibiotic treatment, while the other required hospital admission and removal of the roots. One case of short-term transient lingual paresthesia was also recorded. Two long-term oral exposures were detected, and the root fragments had to be extracted. There were no permanent sensory alterations.
CONCLUSIONS: In our case series of 39 impacted mandibular molars in intimate contact with the IAN and treated with the coronectomy technique, the number of complications was low (two infections and a single case of transient lingual paresthesia), and no permanent sensory alterations were observed. Prospective studies, especially randomized clinical trials, are needed to compare this technique with conventional extraction.
INTRODUCTION: In recent years, thanks to significant advances in basic science and biotechnologies, nephrology has witnessed a deeper understanding of the mechanisms leading to various conditions associated with or causing kidney disease, opening new perspectives for developing specific treatments. These new possibilities have brought increased challenges to physicians, who face with a new complexity in disease characterization and selection the right treatment for individual patients.
AREAS COVERED: We chose four therapeutic situations: anaemia in chronic kidney disease (CKD), heart failure in CKD, IgA nephropathy (IgAN) and membranous nephropathy (MN). The literature search was made through PubMed.
EXPERT OPINION: Anaemia management remains challenging in CKD; a personalized therapeutic approach is often needed. Identifying patients who could benefit from a specific therapy is also an important goal for patients with CKD and heart failure with reduced ejection fraction. Several new treatments are under clinical development for IgAN; interestingly, they target specifically the pathogenetic mechanisms of the disease. The understanding of MN pathogenesis as an autoimmune disease and the discovery of several autoantibodies allows a better characterization of patients. High-sensible techniques for lymphocyte counting open the possibility of more personalized use of anti CD20 therapies.
Patients implanted with a dual-chamber DF-1 cardioverter-defibrillator. Ventricular tachy sensing is performed via an IS-1 pacing lead placed in the interventricular septum.
Pakistani children from age 0 to 6 months who would be growing normally, with WHZ \> 0, to serve as controls. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth.
The invention discloses an acute promyelocytic leukemia cell leukemia DNA vaccine PML-RAP Alpha-hGM-CSF, i.e. the fusion gene pIRES-PMI-RAR Alpha- hGM-CSF. The invention also discloses that the DNA vaccine is applicable in preparing medicine for curing acute promyelocytic leukemia cell leukemia. The invention uses the PML-RAP Alpha fusion gene to construct the DNA vaccine for eradicating the MRD of APL. The invention provides a PML-RAP Alpha-hGM-CSF double-gene DNA vaccine capable of inducing to produce specific anti-APL immune response, which provides important data for research and development of the DNA vaccine for curing APL. The method of the invention can also provide reference for research on other curative tumor DNA vaccines. The DNA vaccine of the invention can clear the minimal residual diseases in the body of APL patients, and finally cure the APL.
This invention relates to compositions that are easily spreadable onto and adhesive to biomembranes. They contain and provide moisture to the biomembranes and do not readily flow off, i.e., leak from the biomembranes. Nor are they readily removed or washed from the biomembranes. Compositions that adhere to and are compatible with, in that they spread, and do not flow off and are not readily removed or washed from the biomembranes are deemed to be bioadhesive. Such compositions are particularly useful for maintaining biomembranes in a moist condition, for lubricating the biomembranes, and for providing a vehicle for containing and delivering medicaments, such as contraceptives, antifungals and antibacterials. The invention further relates to methods for making and methods of use of such compositions. The compositions of this invention are particularly useful for maintaining biomembranes in a moist condition, especially those that are susceptible to dryness, for lubricating the biomembranes and for providing a vehicle for containing and delivering medicaments, such as contraceptives, antifungals and antibacterials.
The present invention relates to a substantially dry, disposable, personal cleansing product useful for both cleansing and conditioning the skin/hair and providing improved fragrance delivery. These articles are used by the consumer by wetting the dry article with water. The article comprises a water insoluble substrate, a lathering surfactant, a nd a fragrance-releasing complex. Preferably, the articles of the present invention further comprise a conditioning component. Use of the substrate enhances lathering at low surfactant levels, increases cleansing and exfoliation, optimizes delivery and deposition of conditioning ingredients, and provides desirable characteristics such as texture, thickness and bulk. As a result, this invention provides effective cleansing using low, and hence less irritating, levels of surfactant while providing superior conditioning benefits by using a substrate having desirable characteristics. The invention also encompasses products further comprising a coating material for encapsulating the fragran ce- releasing complex. The invention also encompasses products comprising various active ingredients for delivery to the skin or hair. The invention also encompasses methods for manufacturing these products.
The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis for culture and characterization of mast cell progenitor cells and their response to various cytokines and anti-mitotic agents. Healthy volunteers and patients will be adults of both sexes from 18 to 70 years of age. Granulocyte colony stimulating factor (G-CSF) will be administered to healthy volunteers at dose of 10 mcg/kg/day as a subcutaneous dose daily for 5 days not to exceed 960mcg. Patients will receive Plerixafor at a dose of 0.24 mg/kg as a single subcutaneous dose not to exceed 24mg the night before leukapheresis as a mobilizing agent for CD34+ cells. In identified patients where leukapheresis yield is considered adequate without stimulation by the principal investigator, leukapheresis may proceed without stimulation. Healthy volunteers will undergo a single leukapheresis at day 7, and patients will undergo a single leukapheresis at day 3 or 4. This is not a therapeutic protocol and does not involve reinfusion of any manipulated cells, viruses or DNA constructs back into human subjects.
Aniline is a widely used chemical. Chronic or high-dose exposure to aniline can lead to hepatocellular damage. Although the hepatic pathogenicity of aniline has been established in previous studies, studies involving pathogenic genes during aniline-induced liver injury are limited. Our study first discovered and identified the role and mechanism underlying a new circRNA mmu_circ_26984 in aniline-induced chemical liver injury. Further, we discuss the protective effect of N-acetylcysteine (NAC) in this pathway. After constructing in vitro and in vivo models of aniline treatment, we screened the circRNA with significant differences in expression in AML12 cells from control and aniline-treated groups by circRNA microarray analysis. Next, using RNA pulldown, liquid chromatography-mass spectrometry (LC-MS), and RNA immunoprecipitation, we analyzed the relationship between mmu_circ_26984 and myosin heavy chain 9 (Myh9). Subsequently, we determined the specific mechanism of action of mmu_circ_26984 and Myh9 in aniline-induced liver injury and the protective effect of NAC against aniline-induced liver injury process using Cell Counting Kit-8, Western blot, RNA extraction, a reverse transcription quantitative polymerase chain reaction (RT-qPCR), fluorescence in situ hybridization, immunohistochemistry, and immunofluorescence. The expression of mmu_circ_26984 was significantly increased in liver tissues and AML12 cells of aniline-treated mice compared with the control group. This high expression of mmu_circ_26984 increased the expression of injury-related inflammatory factors, such as NLRP3, Caspase-1, IL-18, and IL-1β in vivo and ex vivo, which exacerbated the level of liver injury. The interaction of mmu_circ_26984 with Myh9 also affected the course of liver injury. Mmu_circ_26984 overexpression and reduced treatment affected the levels of Myh9 expression in AML12 cells, as well as downstream inflammatory factors associated with injury, such as NLRP3. In addition, NAC reduced the process of liver injury mediated by the mmu_circ_26984/Myh9/NLRP3 axis. In conclusion, mmu_circ_26984 is a potential molecular marker and therapeutic target in the process of aniline-induced liver injury that can mediate aniline-exposure-induced liver injury via modulation of the mmu_circ_26984/Myh9/NLRP3 axis, and NAC can effectively attenuate the effect of this liver injury.
The present invention provides a drug delivery vehicle that can improve the pharmacokinetics of pharmacological agents. The invention relates to a multifunctional carrier capable of delivering a carried material such as a pharmacological agent or genetic material to a recipient. The multifunctional carrier includes a multifunctional core and a plurality of adduct molecules bonded thereto. The molecular carrier has surface functional groups which can be associated with a carried material. The carried material can be associated with the molecular carrier through covalent interactions or ionic interactions. The polyvalent core can be ethylene-diamine tetraacetic acid (EDTA) or succinic acid. The invention also relates to methods for producing and using such molecules.
According to one embodiment, a healthcare information system includes a measurement type storage unit (32), input unit (31), measurement type determination unit (33), acquisition unit (36), and measurement value storage unit (32). The measurement type storage unit (32) stores a plurality of measurement types and healthcare information in association with each other. The input unit (31) inputs healthcare information associated with a monitoring object person. The measurement type determination unit (33) determines a measurement type associated with the input healthcare information in the measurement type storage unit (32). The acquisition unit (36) acquires a measurement value of the monitoring object person associated with the determined measurement type via a healthcare device (1). The measurement value storage unit (32) stores the acquired measurement value.